HOME / Notice / News / EN
NKCL Bio Group, a Korean bio-company that research and develops immune cell therapy, is attracting attention as a beneficiary company of ‘the Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Bio-Pharmaceuticals' (hereinafter referred to as the Advanced Medicine Act). The ...
The Ministry of Food and Drug Safety and the Ministry of Health and Welfare announced on the 25th that the enactment of the Enforcement Decree of ‘The Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals' has passed the cabinet meeting. The Advanced Regener...
As a company that researches immune cell therapy using NK immune cells, NKCL Bio Group targets the $100 billion Immune cell therapy market through its differentiated technological competitiveness. It is leading the mass production and popularization of NK Immune Cell and products through a GMP certif...
NKCL Bio Group has won 2020 Korea Future Management Award in Promising Bio company category. Korea Future Management is to discover and honor the people, companies, and organizations who have outstanding competence in various section of the society, which is organized by The Korea Herald, and Herald ...
Followed by ‘NK Blue Bio Series’, NKCL Bio Group launched ‘NK Cordycep Gold 300’, the anti-cancer and immunity enhancement functional food. ‘NK Cordycep Gold 300’ is a rice powder in which cordycepin is grown within the rice. Cordycepin is a major ingredient of Cordyceps Millitaris. It is known...